GILD · News · 20260910N

HIV and PrEP Demand Growth

GILEAD SCIENCES, INC. · 2026-09-10 · Importance 26 · Surprise 24

Gilead expects continued growth across HIV prevention and treatment, with the Sunlenca launch identified as a long-term HIV growth driver. Management commentary also highlighted ongoing opportunities in HIV prevention alongside treatment and development programs in inflammation, oncology and cell therapy. Sunlenca’s launch broadens the company’s commercial HIV offering beyond existing treatment products.

Key facts

• MarketBeat reported that Gilead sees the Sunlenca launch as fueling long-term HIV growth according to CFO Andy Dickinson at the Cantor Global Healthcare Conference. source
• Gilead's CFO Andy Dickinson said the company sees continued growth opportunities across its HIV prevention and treatment businesses while advancing programs in inflammation, oncology and cell therapy. source